Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Revenue projections:

Revenue projections for BIOCON
Revenue projections for BIOCON

BIOCON is projected to see lower revenues than in the previous year, a trend that usually concerns investors. Declining revenues often harm a company's profitability, leading investors to exercise caution as they weigh the potential risks of continued financial downturns.

Financial Ratios:

currentRatio 0.000000
forwardPE 39.532597
debtToEquity 50.024000
earningsGrowth 4.095000
revenueGrowth 0.092000
grossMargins 0.608710
operatingMargins 0.076250
trailingEps 4.890000
forwardEps 9.072260

BIOCON's forward EPS surpassing its trailing EPS signals that the company is anticipated to be more profitable this year than last. This growth expectation highlights BIOCON's potential for increased earnings and a stronger financial performance in the upcoming year.

Price projections:

Price projections for BIOCON
Price projections for BIOCON

BIOCON's price has continuously remained near the lower end of analysts' projections, indicating that it may be facing challenges in meeting market expectations. This trend raises concerns about the company's future growth trajectory.

Recommendation changes over time:

Recommendations trend for BIOCON
Recommendations trend for BIOCON


Analysts have maintained a buy bias for BIOCON, which could prompt investors to consider the stock as a viable investment. With this positive outlook, BIOCON is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.